JP2015537000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015537000A5 JP2015537000A5 JP2015542037A JP2015542037A JP2015537000A5 JP 2015537000 A5 JP2015537000 A5 JP 2015537000A5 JP 2015542037 A JP2015542037 A JP 2015542037A JP 2015542037 A JP2015542037 A JP 2015542037A JP 2015537000 A5 JP2015537000 A5 JP 2015537000A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- calcium
- receptor
- ligand
- flux agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000000556 agonist Substances 0.000 claims 20
- 230000003185 calcium uptake Effects 0.000 claims 20
- 239000003446 ligand Substances 0.000 claims 13
- 230000028993 immune response Effects 0.000 claims 8
- 210000003491 skin Anatomy 0.000 claims 8
- 102000007863 pattern recognition receptors Human genes 0.000 claims 7
- 108010089193 pattern recognition receptors Proteins 0.000 claims 7
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 claims 6
- 239000003710 calcium ionophore Substances 0.000 claims 6
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical group CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 102000005962 receptors Human genes 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 claims 3
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 244000052616 bacterial pathogen Species 0.000 claims 3
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 claims 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical group O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims 3
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 claims 3
- JZODKRWQWUWGCD-UHFFFAOYSA-N 2,5-di-tert-butylbenzene-1,4-diol Chemical group CC(C)(C)C1=CC(O)=C(C(C)(C)C)C=C1O JZODKRWQWUWGCD-UHFFFAOYSA-N 0.000 claims 2
- CLLKVTAGSOWKHA-UHFFFAOYSA-N 2-[2-(dicyclohexylamino)-2-oxoethoxy]-n,n-dioctadecylacetamide Chemical compound C1CCCCC1N(C(=O)COCC(=O)N(CCCCCCCCCCCCCCCCCC)CCCCCCCCCCCCCCCCCC)C1CCCCC1 CLLKVTAGSOWKHA-UHFFFAOYSA-N 0.000 claims 2
- CNZIQHGDUXRUJS-UHFFFAOYSA-N Cyclopiazonic acid Natural products CC(=C/1C(=O)C2C3C(Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O)O CNZIQHGDUXRUJS-UHFFFAOYSA-N 0.000 claims 2
- 102000003945 NF-kappa B Human genes 0.000 claims 2
- 108010057466 NF-kappa B Proteins 0.000 claims 2
- 102000018546 Paxillin Human genes 0.000 claims 2
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 claims 2
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 claims 2
- CNZIQHGDUXRUJS-DQYPLSBCSA-N alpha-cyclopiazonic acid Natural products CC(O)=C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O CNZIQHGDUXRUJS-DQYPLSBCSA-N 0.000 claims 2
- GOOXRYWLNNXLFL-UHFFFAOYSA-H azane oxygen(2-) ruthenium(3+) ruthenium(4+) hexachloride Chemical compound N.N.N.N.N.N.N.N.N.N.N.N.N.N.[O--].[O--].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].[Ru+3].[Ru+4] GOOXRYWLNNXLFL-UHFFFAOYSA-H 0.000 claims 2
- ZKSIPEYIAHUPNM-ZEQRLZLVSA-N butobendine Chemical compound C([C@H](CC)N(C)CCN(C)[C@@H](CC)COC(=O)C=1C=C(OC)C(OC)=C(OC)C=1)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZKSIPEYIAHUPNM-ZEQRLZLVSA-N 0.000 claims 2
- JTLQADIQVNKIFC-UHFFFAOYSA-N calcium ionophore vi Chemical compound C=1C(C(C)(C)C)=CC=2CC(C=3OCCP(=O)(C=4C=CC=CC=4)C=4C=CC=CC=4)=CC(C(C)(C)C)=CC=3CC(C=3OCCP(=O)(C=4C=CC=CC=4)C=4C=CC=CC=4)=CC(C(C)(C)C)=CC=3CC(C=3OCCP(=O)(C=4C=CC=CC=4)C=4C=CC=CC=4)=CC(C(C)(C)C)=CC=3CC=1C=2OCCP(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 JTLQADIQVNKIFC-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims 2
- 235000002780 gingerol Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- URAUKAJXWWFQSU-UHFFFAOYSA-N n,n-dicyclohexyl-2-[2-(dicyclohexylamino)-2-oxoethoxy]acetamide Chemical compound C1CCCCC1N(C1CCCCC1)C(=O)COCC(=O)N(C1CCCCC1)C1CCCCC1 URAUKAJXWWFQSU-UHFFFAOYSA-N 0.000 claims 2
- LKKJODPUVIMZGC-UHFFFAOYSA-N n-octadecyl-2-[2-[19-[2-[2-(octadecylamino)-2-oxoethoxy]acetyl]-1,4,7,13,16-pentaoxa-10,19-diazacyclohenicos-10-yl]-2-oxoethoxy]acetamide Chemical compound CCCCCCCCCCCCCCCCCCNC(=O)COCC(=O)N1CCOCCOCCOCCN(C(=O)COCC(=O)NCCCCCCCCCCCCCCCCCC)CCOCCOCC1 LKKJODPUVIMZGC-UHFFFAOYSA-N 0.000 claims 2
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 210000004207 dermis Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical group C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725881P | 2012-11-13 | 2012-11-13 | |
| US61/725,881 | 2012-11-13 | ||
| PCT/US2013/069939 WO2014078447A1 (en) | 2012-11-13 | 2013-11-13 | Calcium flux agonists and methods therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018006246A Division JP6625677B2 (ja) | 2012-11-13 | 2018-01-18 | カルシウムフラックスアゴニスト及びその方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015537000A JP2015537000A (ja) | 2015-12-24 |
| JP2015537000A5 true JP2015537000A5 (https=) | 2016-12-08 |
| JP6280129B2 JP6280129B2 (ja) | 2018-02-14 |
Family
ID=50731660
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542037A Active JP6280129B2 (ja) | 2012-11-13 | 2013-11-13 | カルシウムフラックスアゴニスト及びその方法 |
| JP2018006246A Active JP6625677B2 (ja) | 2012-11-13 | 2018-01-18 | カルシウムフラックスアゴニスト及びその方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018006246A Active JP6625677B2 (ja) | 2012-11-13 | 2018-01-18 | カルシウムフラックスアゴニスト及びその方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9463184B2 (https=) |
| EP (1) | EP2919793B1 (https=) |
| JP (2) | JP6280129B2 (https=) |
| KR (3) | KR20170126031A (https=) |
| CN (1) | CN105188716B (https=) |
| AU (1) | AU2013344879B2 (https=) |
| CA (1) | CA2893276C (https=) |
| WO (1) | WO2014078447A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105188716B (zh) * | 2012-11-13 | 2019-02-22 | 河谷控股Ip有限责任公司 | 钙通量激动剂及其方法 |
| WO2014121342A1 (en) * | 2013-02-08 | 2014-08-14 | Luoda Pharma Pty Limited | Methods of treating topical microbial infections |
| US9884087B1 (en) * | 2013-05-03 | 2018-02-06 | Chan Soon-Shiong Nanthealth Foundation | Compositions and methods of improved wound healing |
| US10105305B2 (en) * | 2014-02-19 | 2018-10-23 | The Johns Hopkins University | Compositions and methods for promoting skin regeneration and hair growth |
| US11585805B2 (en) | 2016-02-19 | 2023-02-21 | Nantcell, Inc. | Methods of immunogenic modulation |
| WO2018053432A1 (en) * | 2016-09-19 | 2018-03-22 | Fuller Laboratories | In vitro propagation of babesia microti |
| CN107496420B (zh) * | 2017-08-25 | 2020-07-07 | 中国科学院微生物研究所 | 环匹阿尼酸类生物碱化合物的用途 |
| WO2020232226A1 (en) | 2019-05-16 | 2020-11-19 | The Johns Hopkins University | Compositions and methods for skin rejuvenation |
| CN111840560B (zh) * | 2020-07-24 | 2021-09-03 | 广州医科大学 | 钙离子载体在白癜风治疗中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3960667A (en) | 1972-03-23 | 1976-06-01 | Eli Lilly And Company | Antibiotic A23187 and process for preparation thereof |
| US3873693A (en) | 1974-03-11 | 1975-03-25 | Squibb & Sons Inc | Ionomycin |
| US5489441A (en) * | 1992-01-07 | 1996-02-06 | Procept, Inc. | Method for suppressing immune response associated with psoriasis, contact dermatitis and diabetes mellitus |
| US5238689A (en) * | 1992-01-07 | 1993-08-24 | Procept, Inc. | Use of ruthenium red as immunosuppressive agents |
| TWI268153B (en) * | 2004-06-23 | 2006-12-11 | Univ Nat Cheng Kung | A medicine composition for increasing leukocyte immunity wherein a leukocyte treated by sarcoplasmic/endoplasmic reticulum Ca2+ ATPase |
| GB0505909D0 (en) * | 2005-03-23 | 2005-04-27 | Univ Leeds | Formulations |
| US20070111936A1 (en) * | 2005-11-15 | 2007-05-17 | Vladimir Pak | Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer |
| WO2008070783A2 (en) * | 2006-12-07 | 2008-06-12 | Herbalscience Singapore Pte. Ltd. | Compositions and methods comprising zingiber species |
| US20100105644A1 (en) * | 2008-10-27 | 2010-04-29 | The Regents Of The University Of Michigan | Botanical composition for enhanced skin repair and uses thereof |
| US8764873B2 (en) | 2009-12-07 | 2014-07-01 | James E. Nevin | Nutrient yielding bio-renewable controlled release fertilizer coatings |
| CN102933228A (zh) | 2010-03-15 | 2013-02-13 | 宾夕法尼亚大学董事会 | 制备和储存活化的、成熟树突细胞的体系和方法 |
| US8741642B2 (en) * | 2010-10-22 | 2014-06-03 | Virginia Commonwealth University | Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects |
| CN105188716B (zh) * | 2012-11-13 | 2019-02-22 | 河谷控股Ip有限责任公司 | 钙通量激动剂及其方法 |
-
2013
- 2013-11-13 CN CN201380070113.2A patent/CN105188716B/zh active Active
- 2013-11-13 KR KR1020177032166A patent/KR20170126031A/ko not_active Ceased
- 2013-11-13 KR KR1020157015689A patent/KR20150140625A/ko not_active Ceased
- 2013-11-13 CA CA2893276A patent/CA2893276C/en active Active
- 2013-11-13 US US14/442,392 patent/US9463184B2/en active Active
- 2013-11-13 WO PCT/US2013/069939 patent/WO2014078447A1/en not_active Ceased
- 2013-11-13 AU AU2013344879A patent/AU2013344879B2/en active Active
- 2013-11-13 JP JP2015542037A patent/JP6280129B2/ja active Active
- 2013-11-13 EP EP13854254.3A patent/EP2919793B1/en active Active
- 2013-11-13 KR KR1020197009189A patent/KR20190038679A/ko not_active Ceased
-
2016
- 2016-09-14 US US15/264,947 patent/US9750805B2/en active Active
-
2017
- 2017-08-31 US US15/692,133 patent/US20170360925A1/en not_active Abandoned
-
2018
- 2018-01-18 JP JP2018006246A patent/JP6625677B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015537000A5 (https=) | ||
| WO2013136192A3 (en) | Use of tetracycline compositions for wound treatment and skin restoration | |
| WO2015054619A3 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
| MX2019007956A (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| WO2017042607A3 (en) | Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain | |
| EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
| UA111834C2 (uk) | Лікарська форма | |
| JP2014111603A5 (https=) | ||
| HRP20160427T1 (hr) | Fitokanabinoidi u liječenju raka | |
| WO2015023976A3 (en) | Selective grp94 inhibitors and uses thereof | |
| CL2014002935A1 (es) | Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador | |
| WO2015056094A3 (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent | |
| MX2016008397A (es) | Composicion para usarse en el tratamiento de tos persistente. | |
| WO2015130554A3 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith | |
| BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
| MX357704B (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
| JP2014520892A5 (https=) | ||
| HK1204964A1 (en) | Modulation of factor xa inhibitor mediated blood loss by partial and transient administration of antidote | |
| EP2786765A3 (en) | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor | |
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| UA109944U (uk) | Фармацевтична композиція для зниження рівня n-оксиду триметиламіну | |
| WO2015011653A9 (en) | pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM | |
| RU2012129115A (ru) | Способ лечения острых послеродовых эндометритов у коров | |
| WO2015004634A3 (es) | Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio | |
| AU2014230304A8 (en) | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |